BTK Inhibitors & Beyond: Emerging Research And Treatment Options For Chronic Lymphocytic Leukemia

“BTK inhibitors are the cornerstone of treatment for CLL,” Dr. Georgios Pongas, a hematologist and oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, tells SurvivorNet. He explains that this class of drugs attacks the protein BTK, which is important for the survival of CLL cells.

“These drugs go and bind to this target and inhibit it, so the cancer cell dies,” Dr. Pongas adds. “They are great options in general, both in the frontline setting, meaning for previously untreated patients with CLL, but also in the relapse and refractory setting, meaning when the disease comes back.”

Pirtobrutinib’s Place in the Treatment Path

Currently, pirtobrutinib is used for patients whose CLL has already been treated with another BTK inhibitor, like acalabrutinib or zanubrutinib. It belongs to a newer group of medications called non-covalent BTK inhibitors. Unlike earlier BTK inhibitors, pirtobrutinib attaches to the BTK protein in a different way, allowing it to remain active even when some leukemia cells develop mutations that make older BTK inhibitors less effective.

Because pirtobrutinib has shown promising results in previously treated patients, researchers have studied whether it could also benefit patients earlier in their treatment journey.

In early clinical trials, pirtobrutinib as an initial treatment outperformed older chemotherapy-based regimens and matched a first-generation BTK inhibitor. It has not yet been compared head-to-head against today’s preferred targeted therapies… or newer drugs.

“Right now, pirtobrutinib (Jaypirca) has been approved for patients with relapse disease after the use of one of the BTK inhibitors that are covalently bound to the BTK. However, the only lingering hangup is with sequencing. We don’t know exactly what’s going to happen when you stop responding to pirtobrutinib (Jaypirca),”  Dr. Jacqueline Barrientos, Chief of Hematologic Malignancies at Mount Sinai Medical Center in Miami Beach, explains to SurvivorNet.

The goal is to learn whether these combinations can produce deeper and longer-lasting responses, extend the time before CLL returns, improve long-term outcomes, or allow more patients to complete treatment after a fixed period.

An important question is where pirtobrutinib should fit in the sequence of CLL treatments. If it is used earlier, will it provide better long-term disease control? Could it replace the need for older BTK inhibitors in some patients? Or is it more valuable to reserve pirtobrutinib for later, after another BTK inhibitor stops working, so that patients have an additional effective treatment option available?

These questions are important because doctors want to use each therapy at the time when it provides the greatest benefit while preserving options for the future.

Researchers are also studying whether that approach improves outcomes compared with using currently established treatments first.

The Role of BCL-2 Inhibitors

Beyond pirtobrutinib, entirely new approaches to treating CLL are being explored including next-generation targeted therapies designed to overcome resistance and improve long-term disease control.

Researchers are studying newer BCL-2 inhibitors, bispecific antibodies, which help the immune system recognize and destroy leukemia cells, and CAR T-cell therapy, which uses a patient’s own immune cells that are modified to attack the cancer.

Scientists are also evaluating new combinations of targeted therapies and looking for better ways to personalize treatment — such as using highly sensitive tests to measure how much leukemia remains after treatment to help determine what comes next.

While many of these strategies are still being investigated, they represent exciting areas of research that may further expand treatment options in the future.

The outlook for people living with CLL continues to improve. As research advances, doctors hope to have even more ways to personalize treatment, overcome resistance, and help patients live longer with good quality of life. Ongoing research into pirtobrutinib and other next-generation targeted therapies is helping shape the future of CLL care and may provide more treatment options for patients in the years ahead.

Questions To Ask Your Doctor

• Should I consider a newer treatment option like pirtobrutinib?
• What are my options when treatment stops working?
• What side effects can I expect from targeted therapies?
• Are there any clinical trials testing new approaches I should consider?

Learn more about SurvivorNet's rigorous medical review process.

---